Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Teriparatide

Forteo · PTH (1-34) Fragment

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Teriparatide is FDA-approved (November 2002) recombinant PTH (1-34) and the evidence for fracture reduction in osteoporosis is overwhelming. The pivotal Neer 2001 NEJM Fracture Prevention Trial (n approximately 1,637 postmenopausal women, median 21 months) reduced new vertebral fractures by about 65 percent and non-vertebral fragility fractures by about 53 percent versus placebo, and the trial stopped early after a preclinical rat osteosarcoma signal. The head-to-head VERO trial (Kendler, Lancet 2018) showed fewer new vertebral and clinical fractures than risedronate, and multiple systematic reviews and meta-analyses confirm consistent vertebral and overall non-vertebral fracture reduction, supporting grade 5 for the approved indication.

FDA
FDA Approved (Forteo)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Daily subcutaneous injection; hypercalcemia, orthostatic hypotension, leg cramps, dizziness; expensive. The former 2-year cumulative-use cap and the rat-derived osteosarcoma boxed warning were both revised or removed by the FDA in November 2020 after no human osteosarcoma signal emerged, though osteosarcoma remains a warning in patients with heightened baseline risk.

Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Teriparatide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A PTH (1-34) fragment, FDA-approved for severe osteoporosis and the gold-standard anabolic bone builder. Growing longevity interest for age-related bone loss.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Osteoporosis (approved)
  • Bone density in aging
Osteoporosis at high fracture risk (Forteo)
FDA-approved in 2002 to build bone and reduce fracture risk in postmenopausal women and in men with osteoporosis at high risk of fracture, including those who have failed or cannot tolerate other therapy.
Glucocorticoid-induced osteoporosis
Approved in 2009 for men and women with osteoporosis from long-term steroid use who are at high fracture risk.

How it works

Teriparatide is a fragment of parathyroid hormone, and it exploits a striking quirk of that hormone. Constantly high parathyroid hormone, as in disease, pulls calcium out of bone and weakens it. But given as a single daily injection, the same hormone does the opposite: it switches on osteoblasts, the cells that build bone, producing net new bone. So teriparatide actively builds skeleton rather than merely slowing its loss, which makes it fundamentally different from most osteoporosis drugs.

Teriparatide is a recombinant 34-amino-acid fragment, the active N-terminal portion, the first 34 of the 84 amino acids, of human parathyroid hormone, so it is often written PTH(1-34). It binds the parathyroid-hormone receptor. Sold as Forteo, and now as biosimilars such as Terrosa and the brand Bonsity, it is self-administered as a daily injection from a prefilled pen.

Type
Recombinant PTH(1-34)
Action
Builds bone (anabolic)
Form
Daily injection
Approved
2002 (Forteo)
Boxed warning
Removed 2020
Class
First anabolic agent

The First Drug That Builds Bone, Not Just Saves It

Teriparatide, approved in 2002 as Forteo, was the first bone-building drug for osteoporosis, a genuine milestone. Almost every other osteoporosis treatment is antiresorptive, meaning it slows the breakdown of existing bone, the way bisphosphonates and denosumab do; teriparatide is anabolic, stimulating osteoblasts to lay down new bone, raising bone density and cutting fracture risk. Its history also illustrates good evidence-based regulation. Because very high doses caused bone tumors in rats, the original approval carried a boxed osteosarcoma warning and a two-year lifetime limit. But rats differ sharply from humans, and after roughly fifteen years and millions of treated patients showed no excess osteosarcoma, the FDA removed both the boxed warning and the two-year limit in 2020. Some patient materials still reflect the old limit, but the warning was lifted because the human data did not support it.

Safety in detail

The osteosarcoma concern originates from a lifetime rat carcinogenicity study using high doses, not from human data. Across roughly two decades of clinical trials and post-marketing pharmacovigilance, including large linked pharmacy and cancer-registry cohort studies, no increase in osteosarcoma was observed relative to background population incidence. On that basis the FDA removed the boxed warning in November 2020 and revised the 2-year lifetime limitation, moving osteosarcoma language into the warnings and precautions section.

  • It is generally well tolerated, with transient high calcium, orthostatic dizziness early in dosing, nausea and leg cramps.
  • The rat-based osteosarcoma concern was not seen across millions of treated patients, and the boxed warning and two-year limit were removed in 2020.
  • It is contraindicated in people at high baseline bone-cancer risk, such as those with Paget disease, prior skeletal radiation or open growth plates, and in high calcium or bone metastases.
  • It is a daily injection, a practical burden.
  • It is typically followed by an antiresorptive drug to preserve the bone gained.

Children and teenagers

Teriparatide is not for pediatric use and is specifically avoided in children and young adults with open growth plates, who carry an increased baseline risk of the bone cancer seen with growing bone in animal studies. Any pediatric bone disorder belongs with pediatric specialists using appropriate approved approaches. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Teriparatide’s economy is a legitimate pharmaceutical one: an originator brand and a growing set of biosimilars serving the high-risk and severe-osteoporosis market. As an anabolic agent it is priced above generic bisphosphonates, though biosimilars are bringing costs down. Its commercial story is largely straightforward, an approved, evidence-backed drug whose main access issue is price rather than marketing controversy.

How we got here

Teriparatide is the biologically active 1-34 amino-acid fragment of endogenous human parathyroid hormone, produced by recombinant DNA technology. Eli Lilly first brought it to market as Forteo (Forsteo in Europe) with FDA approval in 2002 for osteoporosis. After the reference patents expired around 2019, biosimilars and follow-on products such as Terrosa, Movymia, Livogiva, and Bonsity reached the market.

Once researchers found that intermittent parathyroid hormone builds rather than depletes bone, teriparatide, the active PTH(1-34) fragment, was developed and tested in fracture trials. It was approved in 2002 as the first anabolic osteoporosis drug, launched with a boxed osteosarcoma warning and a two-year limit drawn from rat data, and gained a glucocorticoid indication in 2009. After roughly fifteen years of reassuring human surveillance, the FDA removed the warning and limit in 2020, and biosimilars followed.

  1. 1990s-2000sIntermittent PTH is shown to build bone, the basis for teriparatide.
  2. 2002Teriparatide is approved as the first anabolic osteoporosis drug, with a boxed warning.
  3. 2009A glucocorticoid-induced osteoporosis indication is added.
  4. 2020The FDA removes the boxed osteosarcoma warning and the two-year limit.
  5. ongoingBiosimilars expand access and lower cost.

The numbers behind the grade

Type
Recombinant PTH(1-34)
Action
Builds bone
Approved
2002
Form
Daily injection
Warning
Removed 2020
Class
First anabolic

The people taking it

The first bone-building, anabolic osteoporosis drug, a recombinant parathyroid-hormone fragment used for high-fracture-risk osteoporosis, whose rat-based osteosarcoma warning was lifted in 2020 after reassuring human data.

Teriparatide’s users are predominantly postmenopausal women with severe or high-fracture-risk osteoporosis, the main population, along with men with osteoporosis, patients with steroid-induced osteoporosis, and people who have failed or cannot tolerate bisphosphonates. It serves an older, high-fracture-risk population.

Approved for high-fracture-risk osteoporosis in postmenopausal women, men and steroid-induced cases. The first anabolic bone agent, now with biosimilars expanding access.

Set against the alternatives

The defining contrast is with antiresorptive drugs like bisphosphonates and denosumab, which slow the breakdown of existing bone; teriparatide instead builds new bone, a fundamentally different and complementary approach often sequenced as anabolic first, then antiresorptive to hold the gains. Against abaloparatide, a parathyroid-hormone-related-protein analog and the newer anabolic, teriparatide is the original, and notably its boxed warning was lifted while abaloparatide’s remained. Against romosozumab, a sclerostin-antibody anabolic, it is an earlier, peptide-based option. Its strength is being the first proven bone-builder; its limitations are the daily injection and cost.

What we do not know

  • What the optimal anabolic-then-antiresorptive sequencing is.
  • How it compares with newer anabolics like abaloparatide and romosozumab.
  • How repeat or longer courses perform now that the two-year limit is gone.
  • How biosimilars will reshape cost and access.

What could change

Post-limit useLonger or repeat courses are reconsidered now that the two-year limit is gone.Newer anabolicsAbaloparatide and romosozumab shape sequencing choices.Biosimilar accessBiosimilars continue to lower cost and broaden use.Optimal sequencingRefining anabolic-then-antiresorptive strategies remains active.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Teriparatide is a prescription osteoporosis medicine given as a daily injection and prescribed by specialists or primary care, the legitimate route. It is reserved for high-fracture-risk or severe osteoporosis or for bisphosphonate failure, is typically followed by an antiresorptive to hold the gains, and is now cheaper through biosimilars.

Teriparatide is priced above generic bisphosphonates as an anabolic specialty drug, though biosimilars are lowering the cost. Price is its main access consideration.

Teriparatide comes from regulated pharmaceutical manufacturing, as the originator and biosimilars, dispensed as refrigerated prefilled pens with full quality assurance.

Originator and biosimilarsForteo and biosimilars such as Terrosa supply the market through pharmacies and specialists.Prefilled pensIt is dispensed as refrigerated prefilled pens for daily self-injection.Cold chainIt requires refrigeration, shaping its distribution.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Teriparatide.

Nothing outstanding on this one.

Sources

The studies that matter

  • The PTH paradoxestablished

    Intermittent daily parathyroid hormone stimulates bone formation, the opposite of the bone loss caused by constantly elevated hormone.

  • Pivotal fracture trialsearly 2000s

    Phase 3 trials showed teriparatide raised bone density and reduced vertebral and non-vertebral fractures.

  • First anabolic approval2002

    Teriparatide was approved as the first bone-building osteoporosis drug, distinct from antiresorptive therapies.

  • Rat osteosarcoma findingpre-approval

    Very high doses in rats increased bone tumors, prompting a boxed warning and a two-year limit at launch.

  • Human surveillance2003-2019

    Surveillance of roughly 2.47 million treated patients found no excess osteosarcoma, supporting removal of the warning and limit in 2020.